What is Agenus Inc. (AGEN) stock price today?

Agenus Inc. (AGEN) is currently trading at $7.67, up 1.72% today.

What is AGEN P/E ratio?

Agenus Inc.'s P/E ratio is 3.66. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is AGEN return on equity (ROE)?

Agenus Inc.'s return on equity (ROE) is -38.12%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Agenus Inc.'s market cap?

Agenus Inc. has a market capitalization of $319.40M.

NASDAQ · Biotechnology

Agenus Inc. (AGEN) Stock

$7.67 +1.72% NASDAQ: AGEN Healthcare

Valuation

Metric	Value
Price	$7.67
Market Cap	$319.40M
P/E Ratio	3.66
P/B Ratio	-2.06
P/S Ratio	3.12
EPS (TTM)	$0.00
52-Week High	$10.31
52-Week Low	$2.71
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-38.12%
ROA	53.28%
ROCE	21.88%
Gross Margin	-18.42%
Operating Margin	-18.42%
Net Margin	69.34%
Debt/Equity	-0.20
Current Ratio	0.41

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$296.0M	$98.0M	$156.0M	$103.0M	$114.0M
Operating Profit	$26.0M	$-179.0M	$-160.0M	$-120.0M	$-21.0M
Net Profit	$-24.0M	$-220.0M	$-246.0M	$-227.0M	$0
EPS	$-2.11	$-15.64	$-13.75	$-10.59	$0.00
Op Margin	8.7%	-183.0%	-102.1%	-116.4%	-18.0%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$466.0M	$414.0M	$314.0M	$226.0M	$227.0M
Total Liabilities	$418.0M	$468.0M	$462.0M	$533.0M	$505.0M
Cash	$292.0M	$179.0M	$76.0M	$40.0M	$3.0M
Borrowings	$58.0M	$78.0M	$93.0M	$95.0M	$335.0M

Latest News

AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot Zacks · Jul 14, 2026 Agenus stock doubles as biotech narrows Phase 3 bet TheStreet · Jul 14, 2026 Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last? Zacks · Jul 14, 2026 Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed? Simply Wall St. · Jul 14, 2026 AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment Stocktwits · Jul 13, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$10.0M	$-175.0M	$-224.0M	$-158.0M	$-158.0M
Investing Cash Flow	$-77.0M	$-87.0M	$-7.0M	$-1.0M	$-1.0M
Financing Cash Flow	$6.0M	$-3.0M	$-4.0M	$74.0M	$84.0M
Net Cash Flow	$192.0M	$-113.0M	$-102.0M	$-36.0M	$-36.0M
Free Cash Flow	$-24.0M	$-228.0M	$-234.0M	$-159.0M	$-159.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.04
EV / EBITDA	2.80
FCF Yield	-50.44%
Quick Ratio	0.41
Interest Coverage	-0.38
Return 1Y	1.98%
Return 3Y	-80.16%
Return 5Y	-95.26%

Ownership

Insiders Held6.72%

Institutions Held23.70%

Institutions Float Held25.41%

Institutional Holder	Shares	Report Date
Vanguard Capital Management LLC	1,440,232	2026-03-31
Vanguard Portfolio Management LLC	1,195,109	2026-03-31
Siren, L.L.C.	1,064,250	2026-03-31
Marshall Wace LLP	688,203	2026-03-31
Blackrock Inc.	545,662	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ABOSAcumen Pharmaceuticals, Inc.	$2.14	+1.90%	-1.24	$154.57M	0.00%
FATEFate Therapeutics, Inc.	$2.18	+2.35%	-2.21	$254.10M	0.00%
HURATuHURA Biosciences, Inc.	$1.96	+1.55%	-3.46	$124.82M	0.00%
INOInovio Pharmaceuticals, Inc.	$1.15	+5.50%	-1.00	$79.46M	0.00%
IRDOpus Genetics, Inc.	$4.65	+4.26%	-3.47	$383.93M	0.00%

About Agenus Inc.

Agenus Inc. is led by CEO Garo H. Armen, employs 316 people, headquartered in US, publicly traded since 2000.

Agenus Inc. (AGEN) stock trades at $7.67 with a market capitalization of $319.40M. The stock is valued at a price-to-earnings (P/E) ratio of 3.66, price-to-book of -2.06, price-to-sales of 3.12. Over the past 52 weeks the stock has ranged between $2.71 and $10.31, and currently trades 25.6% below its 52-week high.

On profitability, Agenus Inc. generates a return on equity (ROE) of -38.12%, return on capital employed of 21.88%, an operating margin of -18.42%, a net profit margin of 69.34%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides